ZYBERNO
Stock Report
Updated Aug 23, 2026

Cellyan Biotechnology Co., Ltd (HKPD)

Consumer Discretionary • NASDAQ

$0.41

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
12.0/100
POOR BUSINESS
Cellyan Biotechnology Co., Ltd (HKPD) scores 12/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):GOOD (0.33x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-7.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Cellyan Biotechnology Co., Ltd (HKPD) stock report — Zyberno Score 12/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.41
Market Cap:$6.68M

Valuation Multiples (3)

P/B Ratio:1.30x
P/S Ratio:0.94x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$8.18M

Price Action & Momentum (3)

Momentum Percentile:3 / 100
% of 52-Week High:15.8%
B. Profitability Assessment

Margin Analysis (1)

Ebitda Margin:-9.2%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.93x
Quick Ratio:2.73x
Cash Ratio:0.06x

Leverage Analysis (3)

Debt To Equity Ttm:0.33x
Debt-to-Equity Ratio:0.33x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-11.17x
Times Interest Earned:-11.17

Capital Structure (4)

Working Capital:5,831,411.00
Cash And Cash Equivalents:190,912.00
Long Term Debt:$1.33M
Net Debt:$1.50M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$7.14M
Cost Of Revenue Ttm:$6.21M

Profitability Breakdown (2)

$930.76K-$701.75K

Bottom Line Performance (3)

$153.74K
Income Before Tax:$0.00
Ebitda Ttm:-654,359.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$18.07K
Interest Expense:62,847.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:-9.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$9.63M
Current Assets:$8.86M
Ppe Net:112,524.00
Goodwill:0.00
Intangible Assets:$90.22K

Liability Structure (4)

Total Liabilities:4,490,399.00
Current Liabilities:3,026,121.00
Long Term Debt:$1.33M
Short Term Debt:$355.47K

Equity & Capital (3)

Equity:$5.14M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:5,092,957.00
Inventory:593,373.00
Accounts Payable:1,227,913.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$244.02K-$279.45K

Investment Activities (1)

Investing Cash Flow:-$42.50K

Financing Activities (3)

Financing Cash Flow:-$269.55K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:$0.01

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.44
Operating Cash Flow Per Share:-$0.01

Book Value & Capital (2)

Book Value Per Share:$0.31
Cash Per Share:0.01

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.74x
Working Capital Turnover Ttm:1.22x

Receivables Management (2)

Receivables Turnover Ttm:1.40x
Days Sales Outstanding Ttm:260.46

Inventory Management (2)

Inventory Turnover Ttm:10.46x
Days Inventory Outstanding Ttm:34.90

Payables & Cash Cycle (2)

Days Payable Outstanding:72.21
Cash Conversion Cycle:223.14
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:65.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:HKPD
Company Name:Cellyan Biotechnology Co., Ltd
Sector:Consumer Discretionary
Industry:Wholesale-Drugs, Proprietaries & Druggists' Sundries
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:16.35M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-23 04:24:20 UTC
Data Timestamp:2026-08-21T21:19:31.659700
Scroll to Top